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Early surgery versus initial conservative treatment in 
patients with spontaneous supratentorial lobar intracerebral 
haematomas (STICH II): a randomised trial
A David Mendelow, Barbara A Gregson, Elise N Rowan, Gordon D Murray, Anil Gholkar, Patrick M Mitchell, for the STICH II Investigators
Summary
Background The balance of risk and beneﬁ t from early neurosurgical intervention for conscious patients with 
superﬁ cial lobar intracerebral haemorrhage of 10–100 mL and no intraventricular haemorrhage admitted within 48 h 
of ictus is unclear. We therefore tested the hypothesis that early surgery compared with initial conservative treatment 
could improve outcome in these patients.
Methods In this international, parallel-group trial undertaken in 78 centres in 27 countries, we compared early 
surgical haematoma evacuation within 12 h of randomisation plus medical treatment with initial medical treatment 
alone (later evacuation was allowed if judged necessary). An automatic telephone and internet-based randomisation 
service was used to assign patients to surgery and initial conservative treatment in a 1:1 ratio. The trial was not 
masked. The primary outcome was a prognosis-based dichotomised (favourable or unfavourable) outcome of the 
8 point Extended Glasgow Outcome Scale (GOSE) obtained by questionnaires posted to patients at 6 months. Analysis 
was by intention to treat. This trial is registered, number ISRCTN22153967.
Findings 307 of 601 patients were randomly assigned to early surgery and 294 to initial conservative treatment; 298 and 
291 were followed up at 6 months, respectively; and 297 and 286 were included in the analysis, respectively. 174 (59%) 
of 297 patients in the early surgery group had an unfavourable outcome versus 178 (62%) of 286 patients in the initial 
conservative treatment group (absolute diﬀ erence 3·7% [95% CI –4·3 to 11·6], odds ratio 0·86 [0·62 to 1·20]; p=0·367).
Interpretation The STICH II results conﬁ rm that early surgery does not increase the rate of death or disability at 
6 months and might have a small but clinically relevant survival advantage for patients with spontaneous superﬁ cial 
intracerebral haemorrhage without intraventricular haemorrhage.
Funding UK Medical Research Council.
Introduction
Spontaneous supratentorial intracerebral haemorrhage 
is a heterogeneous disorder with clinical manifestations 
that range from none to rapid death. It aﬀ ects 4 million 
patients worldwide each year and median case fatality at 
1 month is 40%.1 Many survivors remain severely disabled 
and therefore are an enormous burden on stroke services 
with only a quarter having a good outcome.2
Surgery has the potential to reduce the volume of 
intracerebral haemorrhage and there is clinical and 
experimental evidence that mass removal might reduce 
nervous tissue damage, possibly by relieving local 
ischaemia3–6 or removal of noxious chemicals.7–9 Never-
theless, responses to surgery do not seem to be 
homogeneous, with trial data, expert opinion, and 
mechanistic reasoning all indicating that early surgery 
beneﬁ ts only some clots. For example, large, surgically 
accessible clots exerting a mass eﬀ ect might beneﬁ t 
from early surgery; whereas inaccessible clots, with 
surgical approach paths that cross eloquent speech and 
motor regions probably do not. Therefore, most neuro-
surgeons would remove a large frontopolar intracerebral 
haemor rhage with recent deterioration in conscious-
ness and would not remove a small intracerebral 
haemorrhage in the internal capsule or basal ganglia. 
Also some clots are too small or the patient is too well to 
consider intervention. The hypothesis in the present 
STICH II study was based on the results of a subgroup 
analysis from the ﬁ rst STICH trial that accorded with 
these ideas.10
Several prospective randomised controlled trials11–19 
were undertaken during the previous century, cul min-
ating in the ﬁ rst large trial of early surgery for spon-
taneous supratentorial intracerebral haemor rhage,20 the 
results of which were neutral. This outcome seemed to 
occur because some groups of patients did worse with 
surgery (those with deep-seated bleeds or with intra-
ventricular haemorrhage and hydrocephalus) and some 
better (patients with superﬁ cial lobar haematomas 
without intraventricular haemorrhage).10 The same eﬀ ect 
was noted in a meta-analysis of other studies: a beneﬁ t 
with surgery that was not signiﬁ cant.21
These ﬁ ndings led to the STICH II trial, designed to 
ﬁ nd out whether early surgery would improve outcomes 
compared with initial conservative treatment in patients 
with superﬁ cial lobar supratentorial intracerebral 
haemor rhage without intraventricular haemorrhage. The 
hypothesis was that early surgery could improve outcome 
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in conscious patients in whom there is a superﬁ cial 
intracerebral haemorrhage of 10–100 mL and no evidence 
of intraventricular haemorrhage.
Methods
Trial design and participants
STICH II was an international, multicentre, prospective, 
randomised, parallel group, pragmatic trial as described 
in the protocol.21 129 neurosurgical units in 39 countries 
completed all regulatory requirements and registered for 
participation in this trial.
For the UK, ethics approval was obtained from the 
Scotland Multicentre Research Ethics Committee and 
the Newcastle and North Tyneside Local Research 
Ethics Committee. Elsewhere, appropriate local ethical 
approval was sought from each participating centre 
and the trial was undertaken according to the UK 
Medical Research Council’s good clinical practice 
guide lines and local ethical and research and develop-
ment procedures.
Patients were eligible if they had a spontaneous lobar 
intracerebral haemorrhage on CT scan (≤1 cm from the 
cortical surface of the brain) with a volume of between 
10 mL and 100 mL, were within 48 h of ictus, had a best 
motor score on the Glasgow Coma Score (GCS) of 5 or 6, 
and had a best eye score of 2 or more (ie, were conscious 
at randomisation). They were ineligible if the haemor-
rhage was due to an aneurysm or angiographically 
proven arteriovenous malformation; was secondary to 
tumour or trauma; involved the basal ganglia, thalamic, 
cerebellar, or brainstem regions; or if there was any 
intraventricular blood. Patients were also ineligible if 
they had any severe pre-existing physical or mental 
disabilities or comorbidities that could interfere with the 
assessment of the outcome.
Interventions
Patients were randomly allocated to either early surgery 
or initial conservative treatment. In the early surgery 
group, surgeons were expected to endeavour to undertake 
evacuation of the haematomas within 12 h. In the initial 
conservative treatment group, delayed evacuation was 
permitted if judged clinically appropriate. All patients 
were given the best medical treatment as deﬁ ned 
according to their hospital settings.
Information about the preintracerebral haemorrhage 
status and early progress of all patients (including GCS 
and focal signs for the ﬁ rst 5 days) was gathered by the 
local investigator at 2 weeks, discharge, or death, whichever 
was earliest. Surviving patients had an additional CT scan 
at 5 days (give or take 2 days) to assess changes in the 
haematoma size with and without surgery. Patients’ 
general practitioners (UK) or their local investigators 
(outside the UK) were then contacted at 4 months after 
randomisation to conﬁ rm that the patients were alive, their 
place of residence, and to request completion of a major 
events form.
Randomisation and masking
The Centre for Healthcare Randomised Trials, Aberdeen, 
UK, provided an automatic telephone and internet-based 
randomisation service to assign patients in a 1:1 ratio. 
Patients were stratiﬁ ed by country group and planned 
operation (craniotomy or other) and within these strata 
they were allocated according to a minimisation 
algorithm based on age (<60 years, 60–69 years, or 
≥70 years) and neurological deﬁ cit in the worst aﬀ ected 
arm or leg (normal, weak, or paralysed) with a random 
component such that there was a 20% chance of the 
allocation being reversed.
Patients, relatives, and site investigators were aware of 
which treatment the patient had been allocated to; however, 
at the coordinating centre only the data manager was 
aware of the allocation. Throughout the study, data broken 
down by treatment assignment were never provided to 
investigators or to the study team. Outcome was assessed 
with questionnaires that were completed by the patients or 
their relatives. If it was necessary to administer these 
questionnaires to the patients then the interviewer was 
masked to treatment allocation. Outcome assignment, 
data cleaning, and CT assessment were all completed 
before the treatment assignment was unmasked.
Outcomes
The primary outcome was a prognosis-based favourable 
or unfavourable outcome dichotomised from the 
Extended Glasgow Outcome Scale (GOSE) at 6 months 
after random isation. GOSE was computed from the 
answers to 14 questions in a postal questionnaire 
completed by patients or their relatives.22 The postal 
questionnaires were trans lated into the appropriate 
languages and mailed to patients or their relatives or 
carers at 5 months after random isation and, if needed, 
followed with a reminder at 6 months. In the centres 
where there were problems with the postal systems, 
there were likely to be literacy or lan guage problems, or 
when there had been no response to a reminder, 
questionnaires could be completed by a social worker or 
research nurse, who did not know the treat ment 
allocation, in interview with the patient or relative.
The prognosis-based outcome was designed as a 
diﬀ erential type of outcome with two diﬀ erent levels of 
success.23 The prognostic score was based on GCS, age, 
and haemorrhage volume at randomisation, and the 
algorithm had been developed from patients with a broad 
range of diﬀ erent intracerebral haemorrhages. It was 
calculated as:
10 × GCS – age – 0·64 × volume
The predeﬁ ned cutoﬀ  of 27·67224 for supratentorial 
intracerebral haemorrhage was used to divide the 
patients into a poor prognosis group and a good 
prognosis group. The outcome was judged favourable if 
GOSE was good recovery or moderate disability; 
For the trial protocol see http://
www.trialsjournal.com/
content/12/1/124
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additionally, in the poor prognosis group, upper severe 
disability. This disability represents patients who are 
completely self-caring within their homes but who 
are unable to shop or use public transport without 
assistance.
Secondary outcomes were mortality, time to death, 
prognosis-based dichotomised Rankin (appendix p 4), 
and GOSE, and Rankin and EuroQoL; all measured at 
6 months.
We also report the crossover and major event rates in 
each treatment group.
Statistical analysis
Based on ﬁ ndings from previous work that a prognosis-
based favourable outcome would be noted in 37% of the 
conservative treatment group, a sample size of 566 (283 in 
each group) was needed to show a 12% beneﬁ t from 
surgery (two-sided p<0·05) with 80% power. We therefore 
proposed a sample size of 600 patients to allow for 
withdrawals and crossovers.
The independent data monitoring committee reviewed 
data from the study after 50, 100, 200, and 400 patients 
had been recruited. These interim reviews were con-
ﬁ dential, with only the data manager and the data 
monitoring committee having access to them. The 
committee did not plan any formal interim analyses but 
worked on the principle that a diﬀ erence of at least 
3 SEs in an analysis of a major outcome event (eg, death 
from all causes or independent survival at 6 months) 
would be needed to justify halting or modifying the study 
before the planned recruitment was completed.
The detailed analysis plan has been reported pre-
viously.24 Analysis was undertaken on an intention-to-
treat basis by treatment allocation. Outcomes were 
313 patients eligible 221 consented
92 did not consent
2 excluded* 
4 withdrew
2 excluded* 
307 allocated to early surgery group 294  allocated to initial conservative treatment group 
305 early surgery group (baseline assessment) 292 initial conservative treatment group (baseline assessment)
297 analysed for primary outcome at 6 months 286 analysed for primary outcome at 6 months 
298 followed up at 6 months 291 followed up at 6 months
601 randomly assigned
3984 patients reported
on screening logs
1 withdrew
2 lost to follow-up
1 lost to follow-up
1 alive but status
 not known
5 alive but status
 not known
380 consented
Unknown number of patients 
not reported on logs
2 week follow-up:
288 received allocated intervention
 13 did not receive allocated intervention
2 week follow-up:
229 received allocated intervention
 62 did not receive allocated intervention 
 1 no data available for analysis  
Figure 1: Trial proﬁ le
*One site recruited one patient but had undertaken surgery before randomisation (the patient was allocated to initial conservative treatment); another site recruited 
three patients, and two of these had surgery before randomisation (one allocated to early surgery and one to initial conservative treatment); because of the severe 
breach of protocol all four patients were excluded.
See Online for appendix
For EuroQoL see http://www.
euroqol.org/eq-5d-products/eq-
5d-3l.html
Articles
4 www.thelancet.com   Published online May 29, 2013   http://dx.doi.org/10.1016/S0140-6736(13)60986-1
reported as odds ratios (OR) with 95% CI. Absolute 
diﬀ erences with 95% CI were also reported.
Primary outcome analysis was a simple categorical 
frequency comparison by use of the χ² test for prognosis-
based favourable and unfavourable outcome on GOSE. 
Logistic regression was undertaken to adjust for co-
variates, age, GCS, volume of haematoma, and neuro-
logical deﬁ cit.
Secondary analysis consisted of a Kaplan-Meier sur-
vival curve with log-rank test, χ² test for mortality at 
6 months, and 6 month prognosis-based Rankin. 
Additionally, GOSE, Rankin, and EuroQoL were reported 
by treatment allocation.
We also did a sensitivity analysis based on a proportional 
odds model.
Prespeciﬁ ed subgroup analyses were also undertaken 
for age (<65 years, ≥65 years), volume of haematoma 
(≤35 mL, >35 mL), GCS (8–12, 13–15), time from ictus 
to randomisation (<21 h, ≥21 h), and severity of neuro-
logical deﬁ cit in worse limb (normal, weak, paralysed). 
An additional analysis of the two prognosis groups was 
undertaken.
This trial is registered, number ISRCTN22153967.
Early surgery 
group (n=305)
Initial conservative 
treatment group 
(n=292)
Age (years)
Median (IQR; range) 65 (55 to 74; 
17 to 90)
65 (56 to 74;
23 to 94)
Mean (SD) 63·9 (13·0) 63·9 (13·7)
<60 105 (34%) 106 (36%)
60–69 89 (29%) 70 (24%)
≥70 111 (36%) 116 (40%)
Sex
Male 174 (57%) 166 (57%)
Female 131 (43%) 126 (43%)
Preintracerebral haemorrhage Rankin*
0 240 (80%) 236 (81%)
1 41 (14%) 37 (13%)
2 17 (6%) 11 (4%)
3 2 (<1%) 5 (2%)
4 1 (<1%) 2 (<1%)
Preintracerebral haemorrhage mobility*†
Able to walk 200 m 283 (94%) 275 (95%)
Able to walk indoors 17 (6%) 13 (4%)
Unable to walk 1 (<1%) 2 (<1%)
Glasgow Coma Score, eye
2 26 (9%) 27 (9%)
3 69 (23%) 65 (22%)
4 210 (69%) 200 (68%)
Glasgow Coma Score, verbal
1 40 (13%) 44 (15%)
2 36 (12%) 25 (9%)
3 37 (12%) 35 (12%)
4 93 (30%) 96 (33%)
5 99 (32%) 92 (32%)
Glasgow Coma Score, motor
5 83 (27%) 71 (24%)
6 222 (73%) 221 (76%)
Glasgow Coma Score, total
8 12 (4%) 4 (1%)
9 9 (3%) 15 (5%)
10 23 (8%) 21 (7%)
11 32 (10%) 32 (11%)
12 32 (10%) 34 (12%)
13 46 (15%) 43 (15%)
14 70 (23%) 68 (23%)
15 81 (27%) 75 (26%)
(Continues on next page)
Early surgery 
group (n=305)
Initial conservative 
treatment group 
(n=292)
(Continued from previous page)
Localising arm
Normal 84 (28%) 82 (28%)
Weak 129 (42%) 116 (40%)
Paralysed 92 (30%) 94 (32%)
Localising leg
Normal 94 (31%) 96 (33%)
Weak 141 (46%) 121 (41%)
Paralysed 70 (23%) 75 (26%)
Neurological deﬁ cit
Normal 80 (26%) 81 (28%)
Weak 129 (42%) 112 (38%)
Paralysed 96 (31%) 99 (34%)
Medical history
Documented hypertension 
(>140 mm Hg/90 mm Hg)*
204 (68%) 196 (67%)
On antihypertensive medication* 144 (48%) 150 (52%)
Previous myocardial infarction* 18 (6%) 14 (5%)
Previous stroke* 30 (10%) 33 (11%)
Medication before intracerebral haemorrhage*
Anticoagulant drugs 22 (7%) 20 (7%)
Antiplatelet drugs 42 (14%) 31 (11%)
Thrombolytic drugs 4 (1%) 2 (<1%)
Prognostic score
Median (IQR; range) 42·5 (20 to 62; 
–57 to 120)
41·2 (16 to 63; 
–53 to 121)
Mean (SD) 38·6 (30·7) 39·0 (31·7)
Prognostic score category
Poor 104 (34%) 105 (36%)
Good 201 (66%) 187 (64%)
For continuous variables, data are median (IQR; range) and mean (SD); for 
categorical variables, data are number (%). *Data were missing for four patients 
in the early surgery group who withdrew after randomisation and for one patient 
in the initial conservative treatment group for whom no 2 week data were 
obtained. †One patient in the initial conservative treatment group did not 
provide this information.
Table 1: Baseline characteristics of patients
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Role of the funding source
Neither the sponsor nor the funder of the study had any 
role in study design, data gathering, analysis, and inter-
pretation, or writing of the report. The corresponding 
author and ENR had full access to all the data in the study 
and all members of the writing committee had respon-
sibility for the decision to submit for publication.
Results
601 patients from 78 centres in 27 countries were randomly 
assigned between Jan 11, 2007, and Aug 15, 2012: 307 to 
early surgery and 294 to initial conservative treatment; 
recruit ment by centre is shown in the appendix p 2. Four 
patients were excluded because they were recruited by two 
centres that randomly assigned patients after evacuating 
the haematoma: a serious protocol violation (ﬁ gure 1). All 
other patients were included in the analysis irrespective of 
the decision of the central CT reading committee about 
their eligibility (the CT committee’s ﬁ ndings will be 
reported later in a separate paper). This analysis, therefore, 
includes 305 patients assigned to early surgery and 292 to 
initial conservative treatment (ﬁ gure 1). Table 1 shows 
details of the patients’ age, sex, previous medical history, 
and neuro logical status. The two groups were well matched 
at baseline. 57% were men and the median age of the 
patients was 65 years (range 17–94; table 1). Patients were 
randomly assigned within 48 h of ictus and a quarter 
(76 [25%] of 305 in the early surgery group and 73 [25%] of 
292 in the initial conservative treatment group) were 
assigned within 12 h (median 21·6 h [IQR 12·0–31·5] and 
21·0 [12·0–32·0], respectively). 50% of the patients in the 
early surgery group and 49% in the initial conservative 
treatment group had a GCS of 14 or 15 at randomisation 
(table 1). The planned method of evacuation in 98% of all 
cases was craniotomy. Table 2 shows the haematoma 
characteristics reported by site investigators at random-
isation. The median volume of the haematoma (with the 
Broderick method25) was 36 mL (23·0–55·5) and the 
median depth from the cortex surface was 1 mm (0–2).
Four patients withdrew from the study after allocation 
to early surgery group because they or their relatives 
refused surgery and further involvement, and all data for 
Early surgery group 
(n=305)
Initial conservative 
treatment group (n=292)
Volume (mL)
Median (IQR; range) 38 (24–54; 10–100) 36 (22–58; 10–100)
Mean (SD) 41·4 (21·2) 41·0 (22·9)
Depth (mm)
Median (IQR; range) 1 (0–2; 0–10) 1 (0–2; 0–10)
Mean (SD) 1·6 (2·4) 1·6 (2·5)
Side of haemorrhage*
Left 158 (52%) 149 (51%)
Right 147 (48%) 142 (49%)
For continuous variables, data are median (IQR; range) and mean (SD); for 
categorical variables, data are number (%). *Data were missing for one patient in 
the initial conservative group for whom no forms were returned.
Table 2: Characteristics of haematomas
Early surgery group
(n=288)
Initial conservative 
treatment group (n=62)
Surgery
Craniotomy 284 (99%) 59 (95%)
Craniectomy 1 (<1%) 3 (5%)
Minimally invasive* 3 (1%) ··
Any other procedure 15 (5%) 6 (10%)
Paralysed and sedated 20 (7%) 7 (11%)
Preoperative Glasgow Coma Score, eye†
1 7 (3%) 20 (36%)
2 23 (9%) 20 (36%)
3 62 (23%) 11 (20%)
4 176 (66%) 4 (7%)
Preoperative Glasgow Coma Score, verbal†
1 35 (13%) 24 (44%)
2 30 (11%) 11 (20%)
3 33 (12%) 12 (22%)
4 83 (31%) 6 (11%)
5 87 (33%) 2 (4%)
Preoperative Glasgow Coma Score, motor†
1 ·· ··
2 ·· 1 (2%)
3 1 (<1%) 11 (20%)
4 5 (2%) 14 (25%)
5 69 (26%) 24 (44%)
6 193 (72%) 5 (9%)
Preoperative arm†
Normal 75 (28%) 2 (4%)
Weak 116 (43%) 10 (19%)
Paralysed 76 (28%) 40 (77%)
Preoperative leg†
Normal 82 (31%) 2 (4%)
Weak 129 (48%) 12 (24%)
Paralysed 56 (21%) 38 (73%)
Preoperative speech†
Normal 121 (48%) 5 (15%)
Dysarthric 60 (24%) 14 (41%)
Aphasic 70 (28%) 15 (44%)
Time randomisation to surgery (h)
Median (IQR; range) 3·3 (1·9–5·7; 0·2–34·6) 22·8 (5·6–68·8; 0·6–249·6)
Mean (SD) 4·5 (4·3) 45·5 (56·0)
Surgery within 12 h of randomisation 281 (98%) 23 (37%)
Time from ictus to surgery (h)
Median (IQR; range) 26 (15·3–35·3; 2·5–69·0) 46 (21·7–81·9; 5·0–266·5)
Mean (SD) 26·7 (13·6) 64·2 (58·9)
Surgery within 12 h of ictus 48 (17%) 9 (15%)
For continuous variables, data are median (IQR; range) and mean (SD); for categorical variables, data are number (%). 
*Minimally invasive procedures were burrhole with endoscopic evacuation in two patients and keyhole evacuation in one 
patient. †These questions were not answered for patients who were paralysed and sedated at that time and data were not 
recorded for some other patients.
Table 3: Surgery details
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one patient in the initial conservative treatment group 
were lost by the centre (ﬁ gure 1). Thus, process data were 
available for 301 patients in the early surgery group and 
291 in the initial conservative treatment group. Another 
patient withdrew (self-discharged) in the early surgery 
group between 2 weeks and the 6 month follow-up 
because the patient did not want to have surgery 
(ﬁ gure 1). Nine patients were lost to follow-up (although 
six were known to be alive at 6 months and could be 
included in survival analyses; ﬁ gure 1). Thus, 583 patients 
had complete follow-up at 6 months for the primary 
outcome analysis.
Of the 301 assessable patients in the early surgery group, 
288 (96%) had surgery and 281 (93%) had surgery within 
12 h (table 3). 13 (4%) patients did not have surgery because 
their families refused (n=6), or they had a rebleed or 
intraventricular haemorrhage (3), cardiac problem, respi r-
atory problem, or fever (3), and logistical problems (1). Of 
291 assessable patients in the initial conservative treatment 
group, 62 (21%) had surgery (table 3). Reasons for these 
patients requiring operation were deterioration in GCS 
(n=36), oedema (1), rebleed (3), deterioration and oedema 
(7), deterioration and rebleed (5), deterioration, oedema, 
and rebleed (4), rise in intracranial pressure (2), surgeon 
error (1), family request (2), and an underlying cause (1). 
Craniotomy was the most commonly used surgical 
technique for evacuation in 343 (98%) of 350 of cases.
Comparison of patients in the initial conservative 
treatment group who had surgery with those who did 
not showed that they were more likely to undergo 
surgery if they had a paralysed limb at randomisation 
(34 [55%] of 62 vs 65 [28%] of 229; p<0·0001), lower GCS 
(median 13 [IQR 10–14] vs 14 [12–15]; p<0·0001), larger 
haematoma (54 mL [35–74] vs 32 mL [20–50]; p<0·0001), 
or were in the poor prognosis group (34 [55%] vs 71 [31%]; 
p=0·0005). Patients who crossed over to surgery were 
more likely than were those allocated to early surgery to 
have a GCS of at least one point lower just before their 
operation than at randomisation (47 [82%] of 57 vs 
50 [19%] of 269; p<0·0001).
At 2 weeks, the status of patients was classiﬁ ed as dead, 
still on a neurosurgical ward, transferred to another unit or 
hospital, or discharged. There were signiﬁ cant diﬀ erences 
between the early surgery group and initial conservative 
group (p=0·02). In the early surgery group, 16 (5%) of 
301 patients had died, 85 (28%) were still on a neurosurgical 
ward, 80 (27%) were transferred, and 120 (40%) were 
discharged, whereas in the initial conservative treatment 
group 29 (10%) of 291 patients had died, 102 (35%) were 
still on a neurosurgical ward, 60 (21%) were transferred, 
and 100 (34%) were discharged. Few patients in either 
group (four [1%] of 301 in the early surgery group and one 
[<1%] of 291 in the initial conservative treatment group) 
were treated with factor VIIa. Patients in the initial 
conservative group were more likely to have an angiogram 
(108 [37%] of 291 vs 87 [29%] of 301; p=0·034). However, 
clinically signiﬁ cant lesions were only found in ten 
patients: three with an arteriovenous malformation and 
three with an aneurysm in the early surgery group, and 
three patients with an arteriovenous malformation and 
one with an aneurysm in the initial conservative treatment 
group. Post-randomisation adverse events reported during 
the hospital stay before the 2 week point were similar in 
the two groups: overall 37 (6%) of 592 patients had a 
further intracerebral haemorrhage increasing the volume 
by at least 20% (14 in the early surgery group and 23 in the 
Early surgery group Initial 
conservative 
treatment group
p value Absolute 
diﬀ erence 
(95% CI)
Primary outcome 297 286
Prognosis based 0·367* 3·7% 
(–4·3 to 11·6)
Unfavourable 174 (59%) 178 (62%) ·· ··
Favourable 123 (41%) 108 (38%) ·· ··
Secondary outcomes 298 291
Mortality at 6 months 0·095* 5·6% 
(–1·0 to 12·2)
Dead 54 (18%) 69 (24%) ·· ··
Alive 244 (82%) 222 (76%) ·· ··
Prognosis-based modiﬁ ed 
Rankin
0·456* 3·1%
(–5·0 to 11·2)
Unfavourable 155 (53%) 158 (56%) ·· ··
Favourable 140 (47%) 126 (43%) ·· ··
GOSE 0·091*; 
0·075†
··
Dead 54 (18%) 69 (24%) ·· ··
Vegetative 0 0 ·· ··
Lower severe disability 64 (22%) 66 (23%) ·· ··
Upper severe disability 72 (24%) 59 (21%) ·· ··
Lower moderate disability 20 (7%) 15 (5%) ·· ··
Upper moderate disability 32 (11%) 35 (12%) ·· ··
Lower good recovery 37 (12%) 26 (9%) ·· ··
Upper good recovery 18 (6%) 16 (6%) ·· ··
Rankin 0·128*; 
0·147†
··
0 20 (7%) 16 (6%) ·· ··
1 54 (18%) 57 (20%) ·· ··
2 58 (20%) 41 (14%) ··
3 35 (12%) 32 (11%) ·· ··
4 40 (14%) 28 (10%) ·· ··
5 34 (12%) 41 (14%) ·· ··
Dead 54 (18%) 69 (24%) ·· ··
EuroQoL Index 235 210 0·751‡ ··
Median (IQR; range) 0·64 (0·20 to 0·85; 
–0·59 to 1·00)
0·69 
(0·08 to 0·82; 
–0·59 to 1·00)
·· ··
Data are number or number (%), unless otherwise indicated. EuroQol utility index was calculated with UK weightings 
provided by the EuroQol Group Foundation. Absolute diﬀ erences (95% CIs) are provided for binary outcomes. Rankin 
was not available for three patients in the early surgery group and for seven in the initial conservative group. GOSE was 
not available for one patient in the early surgery group and ﬁ ve patients in the initial conservative group. 
GOSE=Extended Glasgow Outcome Scale. *χ2 test. †Proportional odds model. ‡Mann-Whitney test.
Table 4: Prespeciﬁ ed outcomes at 6 months
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initial conservative treatment), six (1%) had an ischaemic 
stroke (ﬁ ve and one, respectively), six (1%) a pulmonary 
embolism (one and ﬁ ve, respectively), 16 (3%) a major 
cardiac event (nine and seven, respectively), and 71 (12%) 
pneumonia (31 and 40, respectively).
With the prognosis-based dichotomy of GOSE, 123 (41%) 
of 297 patients in the early surgery group had a favourable 
outcome at 6 months compared with 108 (38%) of 286 
patients in the initial conservative treatment group 
(OR 0·86, 95% CI 0·62 to 1·20; p=0·367). Early surgery 
had an absolute beneﬁ t of 3·7% (table 4) and a relative 
beneﬁ t of 9·7% (–11·4 to 30·8). Adjustment for the 
covariates age, GCS, haemorrhage volume, and neuro-
logical deﬁ cit made little diﬀ erence to the prognosis-based 
outcome (0·85, 0·59 to 1·22; p=0·384).
The mortality rate at 6 months was 18% in the early 
surgery group and 24% in the initial conservative 
treatment group (table 4; OR 0·71, 95% CI 0·48 to 1·06; 
p=0·095); absolute diﬀ erence in favour of early surgery 
was 5·6% (table 4) and the relative diﬀ erence was 7·3% 
(–1·3 to 16·0). The actual survival advantage during the 
ﬁ rst 6 months with early surgery was not signiﬁ cant 
(ﬁ gure 2). 27 (9%) of 298 patients died at 30 days and 
43 (14%) at 90 days in the early surgery group, whereas 
43 (15%) of 291 patients died at 30 days and 63 (22%) at 
90 days in the initial conservative treatment group.
Table 4 shows the full extended GOSE, Rankin, and 
EuroQoL by treatment group. The prognosis-based 
Rankin showed favourable outcome in 47% of the 
patients in the early surgery group and in 44% of those in 
the initial conservative treatment group (p=0·46; table 4); 
the absolute diﬀ erence in favour of early surgery was 
3·1% (table 4) and the relative diﬀ erence was 7·0% 
(95% CI –11·4 to 25·3). The actual distribution of GOSE 
was more favourable for the early surgery group than for 
the initial conservative treatment group (ﬁ gure 3), 
although the diﬀ erence was not signiﬁ cant (p=0·091; 
table 4). The proportional odds model analysis of these 
data (OR 0·77, 95%CI 0·58 to 1·03; p=0·075) was 
consistent with the χ² trend analysis.
Figure 4 shows prespeciﬁ ed subgroup analyses and 
analyses for the poor and good prognosis groups. No 
prespeciﬁ ed subgroups showed heterogeneity of treat-
ment response.
At 6 months, 79 (39%) of 203 patients in the poor 
prognosis group died and 67 (33%) had lower severe 
disability, whereas 44 (12%) of 380 patients died in the 
good prognosis group and 63 (17%) had lower severe 
disability. Patients in the good prognosis group were 
much more likely to have a good recovery (85 [22%] of 
380) or moderate disability (89 [23%]) than were those in 
the poor prognosis group (12 [6%] of 203 and 13 [6%], 
respectively). Subgroup analysis of the prognosis-based 
prediction group showed signiﬁ cant heterogeneity 
(I²=79%, p=0·03). Patients in the poor prognosis group 
were more likely to have a favourable outcome with early 
surgery than with initial conservative treatment (OR 0·49, 
95% CI 0·26–0·92; p=0·02; ﬁ gure 4). By contrast, there 
was no advantage for surgery in the good prognosis 
group (1·12, 0·75–1·68; p=0·57).
There were diﬀ erences in the causes of death between 
the two groups. Patients in the early surgery group were 
more likely to die from cardiac events (14 [26%] of 54 vs 
ﬁ ve [7%] of 69) and less likely to die from intracerebral 
haemorrhage or rebleed (eight [15%] vs 20 [29%]), chest 
Figure 2: Kaplan–Meier survival curve
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Figure 4: Subgroup analysis Forest plot
GCS=Glasgow Coma Score.
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infection (13 [24%] vs 20 [29%]), or a pulmonary embolism 
(two [4%] vs nine [13%]) than were those in the initial 
conservative treatment group. There were an additional 
139 serious adverse events reported in 107 patients 
(appendix p 1), with no diﬀ erences between the treatment 
groups. The most common adverse events were 
respiratory infection in eight patients in the early surgery 
group and 12 in the initial conservative group, intra-
cerebral haemorrhage or rebleed in nine and 12, 
respectively, neurological deterioration in nine and 17, 
respectively, seizures in ten and ﬁ ve, respectively, and 
cardiac events in four and eight, respectively.
Discussion
In STICH II, using the prognosis based outcome, we 
did not ﬁ nd signiﬁ cant evidence to support our 
hypothesis that early surgery compared with initial 
conservative treat ment (with delayed surgery if the 
patient deterior ates) improves outcome in conscious 
patients in whom there is a superﬁ cial intracerebral 
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Figure 5: Updated meta-analysis of 15 trials of surgery in patients with intracerebral haemorrhage (A) and individual patient data in cases of lobar 
haematomas without intraventricular haemorrhage (B)
Data are n/N, unless otherwise indicated. Reported outcomes were unfavourable outcome in (A) and death or disability in (B). df=degrees of freedom.
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haemorrhage of 10–100 mL and no evidence of 
intraventricular haemorrhage.
The prespeciﬁ ed recruitment target was attained in 
the STICH II trial and a follow-up rate of 98% was 
achieved at 6 months. Historically, recruitment and 
power are diﬃ  cult and ubiquitous issues in surgical 
trials. The proportional odds model is sensitive to 
diﬀ erences across the outcome scale rather than just to 
those in the primary dichotomy (favourable or 
unfavourable). That this analy sis gives a lower p value 
than the primary outcome suggests insuﬃ  cient power 
might have been an issue; however, this trial was 
powered to detect a 12% diﬀ erence in outcome and took 
67 months to reach the target sample size. If the 4% 
diﬀ erence was regarded as clinically signiﬁ cant it would 
require many more patients.
Interpretation of many surgical trials is also complicated 
by crossovers from conservative treatment to surgery as 
commonly seen in spinal, cardiac, and neurosurgical 
trials.20,26,27 In STICH II, 62 (21%) of 291 patients assigned 
to initial conservative treatment went on to have delayed 
surgery. At the time of the delayed surgery, the patients 
were in deeper coma with worse neurological deﬁ cits than 
were those in the early surgery group (table 3). The 
crossover to surgery from initial conservative treatment 
might therefore have rescued these patients from what 
otherwise might have been a fatal outcome, but because of 
the intention-to-treat analysis they remained in the initial 
conservative treatment group.
The absence of a signiﬁ cant diﬀ erence between the two 
groups in this trial might be because of the case mix of 
patients: more than half were fully conscious or just 
confused; such patients perhaps could be safely observed 
and delayed surgery undertaken only if their state 
deteriorates. There is evidence that the lack of eﬀ ect could 
be a consequence of surgery being beneﬁ cial for some and 
not for other patients with an overall average showing 
little diﬀ erence. In secondary analyses, a survival advan-
tage (with no vegetative survivors) was noted for surgery 
throughout the 6 month follow-up (ﬁ gure 2), but it was 
not signiﬁ cant. Mortality rate remained lower with early 
surgery than with initial conservative treatment through-
out. This pattern contrasts with the Kaplan-Meier plot 
from the ﬁ rst STICH trial in which a more diverse group 
of patients with intracerebral haemorrhage was examined 
and there was no diﬀ erence.20 Because we had dichoto-
mised patients’ prognoses as part of the primary outcome 
in the STICH II trial, we looked at the post hoc eﬀ ects of 
surgery in the two prognostic groups. Patients in the 
STICH II trial with a poor prognosis did better with early 
surgery, whereas those with a good prognosis did not 
(ﬁ gure 4). The interaction test was signiﬁ cant (p=0·03), 
but this result needs to be interpreted cautiously because 
the analysis was not prespeciﬁ ed. However, the result 
accords with some surgeons’ preference to initially 
observe patients with a good prognosis thus avoiding 
surgery unless a patient deteriorates later.
Two-thirds of patients in this trial had documented 
hypertension before the intracerebral haemorrhage. 
Almost a quarter of these hypertensive patients were not 
on antihypertensive medication at the time of their ictus.
In STICH II, almost all the patients undergoing 
surgery had craniotomy. Other operative procedures 
include decompressive craniectomy and minimal access 
pro cedures. Use of decompressive craniectomies have 
been reported for patients with intracerebral haemor-
rhage28 but no prospective randomised controlled trials 
have yet been undertaken to compare their eﬀ ect with 
conservative treatment. Other minimally invasive tech-
niques are being tested in ongoing trials, in particular 
stereotactic delivery of tissue plasminogen activator to 
clots to dis solve them29 and tissue plasminogen activator 
assisted clearance of ventricular haemorrhage.30 Almost 
half of all intracerebral haemorrhages are associated with 
intra ventricular haemorrhage and preliminary results 
from CLEAR IVH,31 the precursor to CLEAR III, have 
shown a beneﬁ t for treatment with intraventricular tissue 
plasminogen activator. In the STICH and STICH II trials, 
craniotomy was assessed whereas in the CLEAR III and 
MISTIE trials minimal access techniques were assessed. 
Figure 5 shows the updated meta-analyses for the trials 
of surgery for intracerebral haemorrhage and for the 
subgroup of patients with lobar intracerebral haemor-
rhage and no intraventricular haemorrhage; the results 
are discussed in the panel. However, minimal access 
techniques might be more beneﬁ cial for deeper clots 
Panel: Research in context 
Systematic review
Previously reported meta-analyses36,37 were updated with the addition of data from STICH II 
after conﬁ rmation that there had been no other reports of trials of surgery versus initial 
conservative treatment. STICH II is the 15th pragmatic randomised controlled trial of surgery 
for intracerebral haemorrhage compared with conservative treatment to be reported. 
STICH II (n=597) is of moderate size compared with occlusive stroke trials but in intracerebral 
haemorrhage it is second only in size to STICH (n=1033). Incorporation of the results from 
STICH II (583 patients) with the previous meta-analysis of 14 trials of surgery37 gives a total 
sample size of 3366. The result shows a signiﬁ cant advantage for surgery with an odds ratio 
of 0·74 (95% CI 0·64–0·86; p<0·0001), although there is signiﬁ cant heterogeneity 
(p=0·0002) because the studies included diﬀ erent patient groups and diﬀ erent types of 
surgery. Addition of the STICH II data to a previous individual patient data meta-analysis 
subgroup of patients with a lobar intracerebral haemorrhage and no intraventricular 
haemorrhage38 did not show evidence of heterogeneity (p=0·21) but there was still not a 
signiﬁ cant beneﬁ t from surgery (n=923; 0·78, 0·59–1·02; p=0·07).
Interpretation
The results of the meta-analyses suggest that there is a role for surgery in patients with 
intracerebral haemorrhage, but that there is still some uncertainty about which patients 
beneﬁ t most. The STICH studies diﬀ er from the other trials in that early surgery was 
compared with the option of delayed surgery for patients who later deteriorate. The survival 
advantage for conscious patients with lobar haematomas seems to be greatest when the 
prognosis is poorer (Glasgow Coma Score 9–12) and when randomly assigned within 21 h. 
This slight advantage is lost in patients with a better prognosis perhaps because there is 
time to observe them initially and only operate in those that later deteriorate.
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and intraventricular haemorrhage. Further research is 
warranted to assess the beneﬁ ts of these other surgeries.
 The results of STICH II conﬁ rm that early surgery does 
not increase the rate of death or disability at 6 months 
and might have a clinically relevant survival advantage 
for patients with spontaneous superﬁ cial intra cerebral 
haemor rhage without intraventricular haemorrhage.
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